Septerna plans Phase 1 trial of SEP-204 for first quarter of 2027

PUBT · 1d ago
Septerna plans Phase 1 trial of SEP-204 for first quarter of 2027
  • Septerna selected SEP-204 as its development candidate for Graves' disease and thyroid eye disease.
  • A Phase 1 trial in healthy volunteers is expected to begin in the first quarter of 2027.
  • Preclinical findings showed normalized thyroid hormone levels, reduced thyroid enlargement and less eye protrusion in Graves' disease animal models.
  • SEP-204 was generally well tolerated in animal toxicology studies; its pharmacokinetic profile is expected to support once-daily oral dosing in humans.
  • Initial preclinical results were reported ahead of a planned presentation at the American Thyroid Association annual meeting on November 5, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Septerna Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040800PRIMZONEFULLFEED9869743) on November 04, 2026, and is solely responsible for the information contained therein.